Spike proteinThe funds will help Novavax begin a final-stage study of its vaccine candidate as early as this fall, with as many as 30,000 subjects, according to the statement.The biotech company earlier secured as much as $388 million in May from the Coalition for Epidemic Preparedness Innovations, the single largest contribution from the organization at the time.
The company’s vaccine candidate is meant to provoke the production of antibodies that block the “spike" protein the coronavirus uses to infect host cells.Separately, Regeneron Pharmaceuticals Inc.
secured a $450 million award from the program under the auspices of the US Biomedical Advanced Research and Development Authority, or BARDA.